<DOC>
	<DOCNO>NCT01191723</DOCNO>
	<brief_summary>Compare acute effect QT interval MAP0004 ( Dihydroergotamine Mesylate deliver Oral Inhalation ) Moxifloxacin Placebo .</brief_summary>
	<brief_title>QT Intervals Study Compare Acute Effects Orally Inhaled Dihydroergotamine ( DHE ) , Oral Moxifloxacin , Placebo</brief_title>
	<detailed_description />
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<mesh_term>Dihydroergotamine</mesh_term>
	<criteria>1 . Able provide sign , execute write informed consent 2 . Healthy nonsmoking adult volunteer : Male Female subject 18 45 year old 3 . Female subject practice adequate contraception ( see section 4.4 ) sterile 4 . No known cardiac disease 5 . Normal hemoglobin value 6 . Normal clinically significant 12lead Electrocardiogram Heart rate ≥ 40 ≤ 100 Visit 1 vital sign assessment ( rest ) Subjects QTcF interval duration &lt; 430 msec male &lt; 450 msec female obtain ECG recorder 's measurement screen ECG take least 5 minute quiet rest supine position 7 . Demonstrated ability properly use Tempo® Inhaler 8 . Subject donate blood last 56 day 1 . Contraindication dihydroergotamine mesylate ( DHE ) 2 . History hemiplegic basilar migraine 3 . Family history long QT syndrome 4 . Participation another investigational trial 30 day prior Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Healthy Volunteers</keyword>
</DOC>